Hemab Therapeutics (NASDAQ:COAG) Trading Down 7.4% – What’s Next?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) fell 7.4% during mid-day trading on Wednesday . The company traded as low as $25.00 and last traded at $25.01. 77,936 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 207,198 shares. The stock had previously closed at $27.00.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on COAG shares. Evercore began coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective for the company. The Goldman Sachs Group began coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $36.00 target price on the stock. Jefferies Financial Group initiated coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $39.00 target price on the stock. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Finally, Wedbush initiated coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $41.75.

Hemab Therapeutics Price Performance

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was purchased at an average price of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the transaction, the director directly owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. This trade represents a 77.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 2,902,872 shares of company stock valued at $53,769,784 over the last three months.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.